140 related articles for article (PubMed ID: 24733459)
21. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
MacCallum DM; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
[TBL] [Abstract][Full Text] [Related]
22. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment.
Ehrmann S; Bastides F; Gissot V; Mercier E; Magro P; Bailly E; Legras A
Intensive Care Med; 2005 May; 31(5):738-42. PubMed ID: 15782314
[TBL] [Abstract][Full Text] [Related]
23. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
24. Update on the treatment of cerebral aspergillosis.
Schwartz S; Thiel E
Ann Hematol; 2004; 83 Suppl 1():S42-4. PubMed ID: 15124667
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
[TBL] [Abstract][Full Text] [Related]
26. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.
van de Sande WW; van Vianen W; ten Kate MT; Vissers J; Laurijsens J; Tavakol M; Rijnders BJ; Mathot RA; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2008 Apr; 52(4):1345-50. PubMed ID: 18195059
[TBL] [Abstract][Full Text] [Related]
27. The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.
Ayçiçek A; Cetinkaya Z; Kiyici H; Kenar F; Aşik G; Kiraz N
Eur Arch Otorhinolaryngol; 2009 Nov; 266(11):1703-9. PubMed ID: 19340446
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
30. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
Warn PA; Sharp A; Morrissey G; Denning DW
Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
[TBL] [Abstract][Full Text] [Related]
31. [Cerebral aspergillosis in an HIV-infected patient: unsuccessful outcome despite combined antifungal therapy. ].
Gasch O; Fernández N; Ayats J; Santin M
Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):193-4. PubMed ID: 19306722
[No Abstract] [Full Text] [Related]
32. Disseminated invasive aspergillosis in a patient with acute leukaemia.
Gottfredsson M; Steingrímsdóttir H
Acta Biomed; 2006; 77 Suppl 2():10-3. PubMed ID: 16918060
[TBL] [Abstract][Full Text] [Related]
33. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
34. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
Arendrup MC; Perkhofer S; Howard SJ; Garcia-Effron G; Vishukumar A; Perlin D; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Oct; 52(10):3504-11. PubMed ID: 18644959
[TBL] [Abstract][Full Text] [Related]
35. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
36. Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.
Moretti S; Bozza S; D'Angelo C; Casagrande A; Della Fazia MA; Pitzurra L; Romani L; Aversa F
Antimicrob Agents Chemother; 2012 Aug; 56(8):4268-76. PubMed ID: 22644025
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of sellar aspergillus abscess.
Liu W; Chen H; Cai B; Li G; You C; Li H
J Clin Neurosci; 2010 Dec; 17(12):1587-9. PubMed ID: 20800492
[TBL] [Abstract][Full Text] [Related]
38. Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient.
Fianchi L; Montini L; Caira M; Voso MT; Maviglia R; Posteraro B; Pagano L
Infection; 2008 Feb; 36(1):65-7. PubMed ID: 17926005
[TBL] [Abstract][Full Text] [Related]
39. Multi-azole resistance in Aspergillus fumigatus.
Howard SJ; Webster I; Moore CB; Gardiner RE; Park S; Perlin DS; Denning DW
Int J Antimicrob Agents; 2006 Nov; 28(5):450-3. PubMed ID: 17034993
[TBL] [Abstract][Full Text] [Related]
40. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan.
Tashiro M; Izumikawa K; Minematsu A; Hirano K; Iwanaga N; Ide S; Mihara T; Hosogaya N; Takazono T; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Nishino T; Tsukamoto M; Kakeya H; Yamamoto Y; Yanagihara K; Yasuoka A; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2012 Jan; 56(1):584-7. PubMed ID: 22024829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
